Cas no 67346-49-0 (Arformoterol)

Arformoterol is a long-acting β?-adrenergic receptor agonist (LABA) used primarily as a bronchodilator in the management of chronic obstructive pulmonary disease (COPD). It is the (R,R)-enantiomer of formoterol, exhibiting enhanced selectivity for β?-receptors, which contributes to its efficacy in relaxing airway smooth muscle and improving airflow. Administered via nebulization, arformoterol offers a rapid onset of action and sustained duration, making it suitable for maintenance therapy in patients with reversible airway obstruction. Its enantiomeric purity minimizes off-target effects, reducing the risk of cardiovascular side effects compared to racemic formulations. Arformoterol is particularly valuable for patients requiring consistent bronchodilation with minimized systemic exposure.

Arformoterol structure

Product Name:Arformoterol

CAS No:67346-49-0

MF:C₁₉H₂₄N₂O₄

MW:344.40

MDL:MFCD00864141

CID:820267

PubChem ID:3083544

Update Time:2025-05-19

Arformoterol Chemical and Physical Properties

Names and Identifiers

- Arformoterol base
- (R,R)-Formoterol
- Arformoterol
- Formamide, N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, (2R,3R)-
- (-)-Formoterol
- N-[2-Hydroxy-5-[1(R)-hydroxy-2-[2-(4-methoxyphenyl)-1(R)-methylethylamino]ethyl]phenyl]formamide
- FORMOTEROL [INN]
- ARFORMOTEROL [VANDF]
- (-)-N-(2-HYDROXY-5-((1R)-1-HYDROXY-2-(((1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL)AMINO)ETHYL)PHENYL)FORMAMIDE HYDROGEN (2R,3R)-2,3-DIHYDROXYBUTANEDIOATE
- Fluir
- FORMOTEROL [MI]
- (+-)-2'-Hydroxy-5'-((RS)-1-hydroxy-2-(((RS)-p-methoxy-alpha-methylphenethyl)amino)ethyl)formanilide
- N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide
- CHEBI:408174
- N-(2-hydroxy-5-((R)-1-hydroxy-2-((R)-1-(4-methoxyphenyl)propan-2-ylamino)ethyl)phenyl)formamide
- N-(2-Hydroxy-5-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1-methyl-ethylamino]-ethyl}-phenyl)-formamide
- Oxis
- formoterol
- (+-)-Formoterol
- n-[2-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide
- eformoterol
- UNII-5ZZ84GCW8B
- HSDB 7287
- Arformoterol (INN)
- Q4789167
- D87655
- EN300-174504
- Formamide, N-(2-hydroxy-5-((1R)-1-hydroxy-2-(((1R)-2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)-
- FORMOTEROL R,R-FORM [MI]
- D07463
- Atimos
- N-(2-hydroxy-5-((1R)-1-hydroxy-2-(((2R)-1-(4-methoxyphenyl)propan-2-yl)amino)ethyl)phenyl)formamide
- AKOS015969668
- 5ZZ84GCW8B
- Formamide, N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-
- Racemic formoterol
- MFCD05662345
- DTXSID40110071
- Formoterol [USAN:INN:BAN]
- F91H02EBWT
- SCHEMBL4247
- Foradil
- UNII-F91H02EBWT
- YM-08316
- Perforomist
- Formamide, N-(2-hydroxy-5-(1-hydroxy-2-((2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)-, (R-(R*,R*))-
- arformoterolum
- ARFORMOTEROL [WHO-DD]
- rel-n-[2-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide
- BDBM50151720
- Innovair
- FORMOTEROL [WHO-DD]
- Arformoterol [INN]
- NS00120489
- 73573-87-2
- 67346-49-0
- FORMOTEROL FUMARATE
- DB01274
- Formoterol r,r-form
- FORMOTEROL [HSDB]
- GTPL7479
- FORMAMIDE, N-(2-HYDROXY-5-(1-HYDROXY-2-((2-(4-METHOXYPHENYL)-1-METHYLETHYL)AMINO)ETHYL)PHENYL)-
- formoterol, ((R*,R*)-(+-))-isomer
- CHEMBL1363
- BPZSYCZIITTYBL-YJYMSZOUSA-N
- cid_9912089
- Formoterolum
- FORMOTEROL [VANDF]
- N-{2-hydroxy-5-[(1R)-1-hydroxy-2-({(1R)-1-methyl-2-[4-(methyloxy)phenyl]ethyl}amino)ethyl]phenyl}formamide
- N-{2-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]phenyl}formamide
- H98
- HY-B0010A
- CS-1413
- MDL： MFCD00864141
- Inchi： 1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1
- InChI Key： BPZSYCZIITTYBL-YJYMSZOUSA-N
- SMILES： [C@H](C1C=CC(O)=C(NC=O)C=1)(O)CN[C@H](C)CC1C=CC(OC)=CC=1

Computed Properties

Exact Mass: 344.17400
Monoisotopic Mass: 344.174
Isotope Atom Count: 0
Hydrogen Bond Donor Count: 4
Hydrogen Bond Acceptor Count: 6
Heavy Atom Count: 25
Rotatable Bond Count: 9
Complexity: 388
Covalently-Bonded Unit Count: 1
Defined Atom Stereocenter Count: 2
Undefined Atom Stereocenter Count : 0
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
Topological Polar Surface Area: 90.8A^2
XLogP3: 1.8

Experimental Properties

Color/Form: Gray white solid
Density: 1.233
Boiling Point: 603.2°C at 760 mmHg
Flash Point: 318.6 oC
Refractive Index: 1.616
PSA: 90.82000
LogP: 3.32310

Arformoterol Security Information

Signal Word：Warning
Hazard Statement： H302-H315-H319-H335
Warning Statement： P261-P305+P351+P338

Arformoterol Pricemore >>

Related Categories	No.	Product Name	Cas No.	Purity	Specification	Price	update time
SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd.	R864579-10mg	(R,R)-Formoterol	67346-49-0	≥98.0%	10mg	￥565.20	2022-09-28
TRC	F693443-1mg	(R,R)-Formoterol (Arformoterol)	67346-49-0		1mg	$190.00	2023-05-18
TRC	F693443-10mg	(R,R)-Formoterol (Arformoterol)	67346-49-0		10mg	$1499.00	2023-05-18
SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd.	R46300-10mg	Formoterol	67346-49-0		10mg	￥678.0	2021-09-08
SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd.	R46300-50mg	Formoterol	67346-49-0		50mg	￥2818.0	2021-09-08
SHANG HAI YI EN HUA XUE JI SHU Co., Ltd.	R025317-10mg	(R,R)-Formoterol,98%	67346-49-0	98%	10mg	￥732	2024-05-22
SHANG HAI YI EN HUA XUE JI SHU Co., Ltd.	R025317-50mg	(R,R)-Formoterol,98%	67346-49-0	98%	50mg	￥3337	2024-05-22
SHANG HAI XIAN DING Biotechnology Co., Ltd.	L-VS726-10mg	(R,R)-Formoterol	67346-49-0	≥98.0%	10mg	￥924.0	2022-02-28
SHANG HAI XIAN DING Biotechnology Co., Ltd.	L-VS726-2mg	(R,R)-Formoterol	67346-49-0	≥98.0%	2mg	￥275.0	2022-02-28
MedChemExpress	HY-B0010A-5mg	Arformoterol	67346-49-0	≥98.0%	5mg	￥2900	2024-04-19

Arformoterol Suppliers

Amadis Chemical Company Limited

Gold Member

Audited Supplier

(CAS:67346-49-0)Arformoterol

Order Number:A1036186

Stock Status:in Stock

Quantity:5mg/10mg

Purity:99%

Pricing Information Last Updated:Thursday, 29 August 2024 16:58

Price ($):364.0/577.0

Email:[email protected]

Product Official Link

Arformoterol Related Literature

1. Aggregation-induced emission enhancement in halochalcones?

Patricia A. A. M. Vaz,Jo?o Rocha,Artur M. S. Silva New J. Chem., 2016,40, 8198-8201
2. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes

Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
3. An amino group functionalized metal–organic framework as a luminescent probe for highly selective sensing of Fe3+ ions?

Zhonghua Xiang,Chuanqi Fang,Sanhua Leng,Dapeng Cao J. Mater. Chem. A, 2014,2, 7662-7665
4. An intermolecular C–H oxidizing strategy to access highly fused carbazole skeletons from simple naphthylamines?

Christian K. Rank,Alexander W. Jones,Tatjana Wall,Patrick Di Martino-Fumo,Sarah Schr?ck,Markus Gerhards,Frederic W. Patureau Chem. Commun., 2019,55, 13749-13752
5. An all-solid-state imprinted polymer-based potentiometric sensor for determination of bisphenol S?

Rongning Liang,Tanji Yin,Ruiqing Yao,Wei Qin RSC Adv., 2016,6, 73308-73312

Related Categories

Additional information on Arformoterol

Comprehensive Overview of Arformoterol (CAS No. 67346-49-0): Mechanism, Applications, and Emerging Trends

Arformoterol (CAS No. 67346-49-0), a selective β2-adrenergic receptor agonist, is a long-acting bronchodilator primarily used in the management of chronic obstructive pulmonary disease (COPD) and asthma. Its chemical structure, (R,R)-formoterol, distinguishes it as the active enantiomer of racemic formoterol, offering enhanced efficacy and reduced side effects. The compound’s unique pharmacological profile has made it a subject of interest in respiratory therapeutics, particularly amid rising global concerns over air pollution and respiratory health.

In recent years, the demand for Arformoterol-based treatments has surged, driven by increasing COPD prevalence and patient awareness. Search trends reveal frequent queries such as "Arformoterol vs. salmeterol" and "best bronchodilator for severe asthma," reflecting its clinical relevance. The drug’s ultra-LABA (ultra-long-acting beta-agonist) properties ensure sustained bronchodilation for up to 24 hours, addressing unmet needs in respiratory disease management.

From a molecular perspective, Arformoterol (CAS No. 67346-49-0) binds selectively to β2-receptors in bronchial smooth muscle, activating adenylate cyclase and increasing cyclic AMP. This mechanism relaxes airways, improving airflow and reducing symptoms like wheezing. Notably, its enantiomeric purity minimizes off-target effects on cardiac β1-receptors, a key advantage over older bronchodilators.

Current research explores Arformoterol’s synergy with inhaled corticosteroids (ICS) and anticholinergics, aligning with the GOLD guidelines for COPD combo therapy. Studies also investigate its potential in exercise-induced bronchoconstriction, a hot topic among athletes and fitness enthusiasts. As precision medicine gains traction, Arformoterol’s role in personalized respiratory care is increasingly emphasized.

Manufacturing and formulation advancements have optimized Arformoterol’s delivery via nebulizers and dry powder inhalers (DPIs). Patients frequently search for "how to use Arformoterol nebulizer" or "Arformoterol side effects," underscoring the need for clear patient education. The drug’s stability profile and low systemic absorption further enhance its safety.

In conclusion, Arformoterol (CAS No. 67346-49-0) represents a cornerstone in modern respiratory pharmacotherapy. Its targeted action, coupled with evolving applications, positions it as a vital tool against global respiratory disease burdens. Future directions may include digital health integrations, such as smart inhalers, to optimize adherence and outcomes.

67346-49-0 (Arformoterol) Related Products

Recommended suppliers